Strong data from DSR® proof-of-concept studies in heart

Serial Direct Sodium Removal in Patients with Heart Failure and Diuretic Resistance Ghent, Belgium – 3 April 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that the results from two proof-of-concept studies, RED DESERT and SAHARA, of the Company’s DSR therapy in patients with diuretic-resistant heart failure have been published in the prestigious pe

Related Keywords

United States , Canada , Belgium , American , Cian Crosbie , Jeffrey Testani , Yale University , Company Or Sequanamedical , Company Premarket Approval , Serial Direct Sodium Removal , Heart Failure , Sequana Medical , Euronext Brussels , European Journal , Chief Executive Officer , Seattle Heart Failure , Premarket Approval , North American , Data Safety Monitoring Board , Loop Diuretics , Sr , Linical Studies , Red Desert , The Company , Sequana , Liver Disease , Sahara , Diuretics ,